Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR in Action: A Look at ACR Activities That Support Your Practice

Carina Stanton  |  February 1, 2018

Rheumatologists working in every practice setting face a number of challenges that can seem insurmountable. How do you cost-effectively manage administrative burdens? How do you establish an efficient and effective approach to capturing quality metrics? How do you maintain the critical elements of the care you provide, such as diagnostic musculoskeletal ultrasound and patient access to medications?

Through the work of rheumatology advocates working for and with the ACR and through initiatives with coalition partners, such as the American Medical Association (AMA), the College has made headway with payers and on Capitol Hill to make rheumatology practice more effective for and accessible to members and the patients they serve, according to ACR Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP. One example of the power ACR advocacy efforts have had recently on daily practice: the College’s success with advocating for UnitedHealthCare to continue to reimburse rheumatologists for consultations, after proposing to stop payments for these important services, Dr. Worthing shares.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Here’s a look at several key practice areas in which the ACR’s advocacy efforts have been successful and how practices are reaping the benefits.

Reducing Administrative Burdens
Administrative burdens are widespread in medical practices today on a number of fronts, including electronic medical record use, quality reporting, coding and prior authorization requirements. Reducing the administrative burdens placed on rheumatology practices has long been an ACR priority.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR Committee on Rheumatologic Care (CORC) has been very active in addressing this issue, according to CORC Chair Colin Edgerton, MD, FACP, RhMSUS. “A major issue has been step edit therapy and formulary tiering requiring prior authorizations. CORC has developed a position statement advocating for meaningful and less burdensome cost-mitigation strategies. The ACR Insurance Subcommittee [ISC] communicates these positions directly to insurance companies—responding to member concerns as they arise,” Dr. Edgerton says.

For example, Dr. Edgerton shares that the ISC has been quick to respond to his practice’s concerns regarding burdensome prior authorization programs. “The ISC has scheduled calls and sent letters with significant impact, and ACR staff and volunteers are easy to contact and very responsive,” he acknowledges.

Last year, advocacy efforts by the ACR and other groups led to the passage of step therapy laws in five states and successful advances with federal step therapy legislation in Congress. The ACR, along with coalition partners including the AMA, has successfully advocated for reforms to prior authorization to streamline the process and make it more transparent, and to increase patients’ access to medicines, Dr. Worthing explains. The ACR has also helped create a consensus statement to share the rheumatology perspective on improving the prior authorization process.

Page: 1 2 3 4 5 | Single Page
Share: 

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:ACR advocacybiosimilar pricingdiagnostic MSUSpractice areaspractice supportreducing administrative burdensrheumatology-specific APMRISE registry

Related Articles

    Value-Based Care Continues to Evolve in Rheumatology

    April 24, 2023

    Value-based care in rheumatology continues to evolve, and rheumatologists can stay active with advocacy efforts behind value-based care and other government relations initiatives.

    Marching to the Biosimilar Beat: Questions on Rollout Remain

    September 7, 2023

    The availability of biosimilars for the treatment of patients with rheumatic diseases exploded in 2023. Here’s where we stand and what to expect going forward.

    Report on EU’s Experience with Biosimilar Drugs Released: Will U.S. Experience Be Similar?

    October 17, 2017

    As questions about biosimilar medications swirl among U.S. rheumatologists, a recently released report sheds some light on the European experience with biosimilars—and may offer some important insights for the U.S. market. The report, Biosimilars in the EU: Information Guide for Healthcare Professionals, was released in late April by the European Medicines Agency (EMA) and the…

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    Biosimilars Debate Heats up over Cost Savings, Safety Concerns

    April 15, 2016

    After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences